Brainstorm Cell Therapeutics (BCLI) Competitors $1.41 -0.13 (-8.44%) Closing price 03/21/2025 04:00 PM EasternExtended Trading$1.50 +0.09 (+6.03%) As of 03/21/2025 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BCLI vs. ATHE, OSTX, CELU, CVKD, GBIO, FBRX, MDCX, CASI, NRXP, and ESLAShould you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Alterity Therapeutics (ATHE), OS Therapies (OSTX), Celularity (CELU), Cadrenal Therapeutics (CVKD), Generation Bio (GBIO), Forte Biosciences (FBRX), Medicus Pharma (MDCX), CASI Pharmaceuticals (CASI), NRx Pharmaceuticals (NRXP), and Estrella Immunopharma (ESLA). These companies are all part of the "pharmaceutical products" industry. Brainstorm Cell Therapeutics vs. Alterity Therapeutics OS Therapies Celularity Cadrenal Therapeutics Generation Bio Forte Biosciences Medicus Pharma CASI Pharmaceuticals NRx Pharmaceuticals Estrella Immunopharma Alterity Therapeutics (NASDAQ:ATHE) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, community ranking, profitability, risk and dividends. Does the media prefer ATHE or BCLI? In the previous week, Alterity Therapeutics' average media sentiment score of 0.00 equaled Brainstorm Cell Therapeutics'average media sentiment score. Company Overall Sentiment Alterity Therapeutics Neutral Brainstorm Cell Therapeutics Neutral Which has more risk & volatility, ATHE or BCLI? Alterity Therapeutics has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Do analysts prefer ATHE or BCLI? Alterity Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 218.30%. Brainstorm Cell Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 2,027.66%. Given Brainstorm Cell Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Alterity Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer ATHE or BCLI? Brainstorm Cell Therapeutics received 286 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. However, 62.50% of users gave Alterity Therapeutics an outperform vote while only 60.00% of users gave Brainstorm Cell Therapeutics an outperform vote. CompanyUnderperformOutperformAlterity TherapeuticsOutperform Votes562.50% Underperform Votes337.50% Brainstorm Cell TherapeuticsOutperform Votes29160.00% Underperform Votes19440.00% Is ATHE or BCLI more profitable? Company Net Margins Return on Equity Return on Assets Alterity TherapeuticsN/A N/A N/A Brainstorm Cell Therapeutics N/A N/A -528.56% Which has better valuation and earnings, ATHE or BCLI? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlterity TherapeuticsN/AN/A-$12.54MN/AN/ABrainstorm Cell TherapeuticsN/AN/A-$17.19M-$4.80-0.29 Do institutionals & insiders believe in ATHE or BCLI? 2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by company insiders. Comparatively, 6.7% of Brainstorm Cell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryBrainstorm Cell Therapeutics beats Alterity Therapeutics on 5 of the 9 factors compared between the two stocks. Remove Ads Get Brainstorm Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCLI vs. The Competition Export to ExcelMetricBrainstorm Cell TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.04M$3.05B$5.73B$8.13BDividend YieldN/A1.54%4.39%4.04%P/E Ratio-0.2929.5124.7419.07Price / SalesN/A449.70398.9891.58Price / CashN/A168.6838.1634.64Price / Book-1.184.367.104.43Net Income-$17.19M-$71.72M$3.20B$247.36M7 Day Performance-10.76%-2.75%0.82%0.25%1 Month Performance-15.06%-10.21%3.69%-5.30%1 Year Performance-83.51%-22.37%14.52%3.47% Brainstorm Cell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCLIBrainstorm Cell Therapeutics3.6677 of 5 stars$1.41-8.4%$30.00+2,027.7%-83.5%$8.04MN/A-0.2940News CoverageHigh Trading VolumeATHEAlterity Therapeutics2.4065 of 5 stars$4.03+2.3%$12.00+197.8%+113.0%$35.73MN/A0.0010Positive NewsOSTXOS Therapies1.6838 of 5 stars$1.63+1.2%$17.50+973.6%N/A$35.48MN/A0.00N/ACELUCelularity0.225 of 5 stars$1.49-3.9%N/A-64.9%$35.47M$48.20M0.00220News CoverageCVKDCadrenal Therapeutics2.6236 of 5 stars$19.87+4.1%$32.00+61.0%N/A$35.43MN/A-2.984GBIOGeneration Bio2.8543 of 5 stars$0.53+10.4%$7.33+1,283.6%-84.9%$35.40M$18.58M-0.24150Earnings ReportGap DownHigh Trading VolumeFBRXForte Biosciences3.2526 of 5 stars$5.52-4.8%$23.58+327.2%+29,061.9%$35.29MN/A-0.345Gap DownMDCXMedicus PharmaN/A$2.95-10.3%$10.00+239.0%N/A$35.17MN/A0.00N/AUpcoming EarningsGap DownCASICASI Pharmaceuticals3.845 of 5 stars$2.26+1.8%$6.00+165.5%-27.0%$35.01M$22.06M-1.01180Upcoming EarningsPositive NewsNRXPNRx Pharmaceuticals1.7572 of 5 stars$2.05-12.8%$31.67+1,444.7%-96.3%$34.68MN/A-0.962Upcoming EarningsAnalyst RevisionESLAEstrella Immunopharma2.0068 of 5 stars$0.96+4.0%$16.00+1,571.5%-12.2%$34.63MN/A-3.68N/A Remove Ads Related Companies and Tools Related Companies ATHE Competitors OSTX Competitors CELU Competitors CVKD Competitors GBIO Competitors FBRX Competitors MDCX Competitors CASI Competitors NRXP Competitors ESLA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCLI) was last updated on 3/24/2025 by MarketBeat.com Staff From Our PartnersElon Musk’s NEW Project… RevealedYou won't believe what Elon Musk is hiding… Inside this facility in the middle of an industrial zone of Memphi...InvestorPlace | SponsoredTrump Shock to change everything Is this Trump’s next major move? Millionaire trading expert Imre Gams has found a bill that directs the Uni...Centurion Publishing | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredA new coin is elbowing its way to the top of the crypto worldWith Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
